Group 1 - HHLR Fund, L.P. and its affiliates reduced their stake in BeiGene from 6.03% to 4.89%, no longer being a major shareholder [1] - The reduction in stake began in June 2023, with HHLR Fund having previously held 9.02% of shares [1] - The core reason for the reduction is attributed to the fund's typical investment period of around 10 years, with HHLR's investment in BeiGene exceeding 11 years [1] Group 2 - Hillhouse Capital led a $75 million Series A financing round for BeiGene in 2014 and participated in 8 financing rounds [2] - In Q1 2023, BeiGene reported revenue of 8.048 billion yuan, a 50.2% increase from the previous year, and a significantly reduced net loss of 94.5 million yuan [2] - The revenue growth was driven by product sales, particularly from self-developed products, with a notable increase in sales for Zebrutinib and Tislelizumab [2] Group 3 - BeiGene's CEO indicated that the company expects to achieve positive operating profit for the full year of 2025 [3]

作者： KAIZEN投资之道 来源：雪球 巴菲特的投资哲学从 " 捡烟蒂 " 到聚焦 " 优质公司 " 的转型 ， 既是价值投资理论的自我革新 ， 也是对市场环境与资本规模变化的动态适应 。 这一历程揭示了认知进化 、 护城河构建与长 期复利的核心逻辑 ， 为A股投资者提供了从估值套利转向价值创造的经典范式 。 一 、 投资理念的演变过程与核心启发 1. 早期 " 捡烟蒂 " 策略 ： 安全边际与清算逻辑 风险提示：本文所提到的观点仅代表个人的意见，所涉及标的不作推荐，据此买卖，风险自负。 受格雷厄姆影响 ， 巴菲特早期以 " 市价低于清算价值 " 为标准 ， 投资伯克希尔纺织厂等企业 。 例如 ， 伯克希尔股价7.5美元时 ， 其设备清算价值达19.46美元 ， 看似 " 白捡钱 " 的机会 。 然而 ， 这类公司缺乏成长性 ， 需持续输血维持运营 ， 最终成为拖累 （ 伯克希尔纺织业务 亏损多年后关闭 ） 。 启发 ： 低估值可能伴随隐藏风险 ， 单纯依赖财务数据难以捕捉企业长期价值 。 2. 中期转向 " 优质公司 " ： 护城河与定价权 1972年收购喜诗糖果是转折点 。 该公司虽市盈率较高 ， 但凭 ...

JohnV.Oyler（欧雷强） ，1968年出生，百济神州联合创始人，自2010年起一直担任公司执行董事、董事会 主席兼首席执行官。于1990年获得麻省理工学院的理学学士学位，于1996年获得斯坦福大学的工商管理硕 士学位。欧雷强以管理顾问职务在麦肯锡公司（McKinsey&Company）开始其职业生涯。1997年至1998 年，欧雷强担任GentaIncorporated联席首席执行官，该公司为一家在纳斯达克交易所上市的以肿瘤为重点的 生物制药企业。1998年至2002年，欧雷强创立Telephia,Inc.并担任总裁，该公司于2007年被尼尔森公司 （The Nielsen Company）收购。2002年至2004年，欧雷强担任Galenea Corp的首席执行官，该公司为一家致 力于开发新的中枢神经系统疾病治疗方法的生物制药企业。2005年至2009年，欧雷强担任BioDuro,LLC的总 裁兼首席执行官，该公司为一家药品开发外包公司，后被Pharmaceutical Product Development Inc.收购。 2019年，欧雷强正式入选生物技术产业协会（BIO）董事会及其卫生部门理事 ...

Group 1 - Hillhouse Capital has reduced its stake in BeiGene, selling 16 million shares, bringing its total holdings down to 68.55 million shares, which is 4.89% of the company, no longer making it a major shareholder [1] - The sale occurred on May 9, 2025, at a minimum price of $230.23 per share, resulting in proceeds of approximately $3.68 billion [1] - The stock prices of BeiGene across A-shares, H-shares, and U.S. shares have rebounded this year, with U.S. shares seeing an increase of over 30% [1] Group 2 - Following the reduction of its stake in BeiGene, Hillhouse Capital is set to subscribe to the IPO of Hengrui Medicine [3] - Hengrui Medicine plans to issue 225 million H-shares, with a price range of HKD 41.45 to HKD 44.05 per share, potentially raising up to HKD 13.08 billion [3][4] - The IPO is expected to attract significant interest from international investment institutions, including Hillhouse Capital and others [3] Group 3 - Hengrui Medicine's IPO pricing represents a discount of 19.3% compared to the average A-share price over the past ten days [4] - The company aims for a stable pricing strategy to build investor confidence and ensure successful fundraising, avoiding significant post-listing price volatility [5] - Hengrui Medicine and BeiGene are in a competitive race for the title of "Pharmaceutical King" in the A-share market, with Hengrui currently leading by a market cap of 24 billion yuan as of May 15 [5]

本报记者 王镜茹 传统中医药企业今年一季度迎来业绩"开门红"，引发市场关注。例如，广誉远中药股份有限公司一季度营收、归母净利润 分别为4.17亿元、0.64亿元，同比增长21.48%、53.94%。广誉远相关负责人表示，通过实施简政放权、改革绩效考核政策等举 措，一季度公司各条线、各产品实现普遍增长。 研报显示，目前我国创新药已进入成果兑现阶段，研发进展催化较多，有望持续作为2025年医药板块投资主线；而中药产 业也从依赖规模扩张转向以"技术溢价+标准输出"为特征的高附加值阶段，具备国际循证医学背书和标准化生产能力的龙头企 业将主导全球化竞争格局。 此外，在AI、人形机器人、低空经济等新兴赛道进行前瞻性布局的上市公司，也成为机构调研的重点。祥鑫科技股份有限 公司主营精密冲压模具和金属结构件，5月份以来累计接待170家机构调研。关于未来的盈利点，祥鑫科技相关负责人表示，首 先是智能机器人领域，公司将合作共建"轻量化结构件—关键零部件—本体代工"全链条能力，复制新能源赛道成功路径。其次 是低空经济领域，拟与头部客户达成战略合作，打造新增长曲线。 深圳市雷赛智能控制股份有限公司相关负责人在接受机构调研时表示，公司业 ...

Core Viewpoint - The executive order titled "Providing 'Most Favored Nation' Pricing for Prescription Drugs for American Patients" aims to align U.S. drug prices with those of other developed countries, potentially disrupting the U.S. pharmaceutical market and impacting innovation drug commercialization [2][6][11]. Summary by Sections Executive Order Overview - The executive order mandates the implementation of a "Most Favored Nation" pricing system, allowing U.S. patients to access drug prices equal to or lower than those in other developed nations [2][6]. - It encourages pharmaceutical companies to bypass intermediaries and sell directly to consumers at these prices, while also considering the import of lower-priced drugs from other countries [2][6]. Impact on Medicare and Medicaid - The order primarily affects Medicare and Medicaid, which together account for approximately 40% of U.S. healthcare payments, while commercial insurance covers over 40% [2][3]. - The direct impact on innovative drugs is expected to be limited in the short term, as these are mainly covered by commercial insurance, which the order does not directly influence [3][11]. Market Dynamics and Pharmaceutical Strategies - The order could lead to a shift in how pharmaceutical companies approach market rights, with a potential focus on retaining global rights rather than just overseas rights to control drug development and pricing [4][11]. - There is concern that if the order is implemented, some new drugs may only be launched in the U.S., delaying or preventing their availability in other regions [4][11]. Financial Implications - The U.S. accounts for about 75% of global pharmaceutical profits, and the order aims to address the imbalance where American consumers subsidize lower prices in other countries [6][7]. - The executive order states that Americans should not pay significantly higher prices for identical drugs produced in the same facilities [6][7]. Innovation Drug Market Outlook - The executive order may lead to a decrease in investment in U.S. innovation drugs, potentially increasing reliance on Chinese drug development [11]. - The high payment capacity of the U.S. market, which has historically supported high drug prices, may be challenged, affecting the dynamics of global drug pricing and availability [11]. Case Study: Zebutine - Zebutine, a BTK inhibitor, has seen significant sales growth, with global sales exceeding $4.7 billion and projected U.S. sales of $2 billion in 2024 [10]. - The drug's pricing strategy in the U.S. aligns with that of its competitors, but the potential changes in pricing dynamics could impact future pricing strategies and market access [10][11].

5月12日晚，美国总统特朗普发布了一项名为"为美国患者提供'最惠国待遇'处方药定价"的行政令。 这项行政令明确，要在美国实行"最惠国价格"制度，即美国患者享受与其他发达国家相同或更低的药品价格；鼓励药企绕过中间商，直接以"最惠国价格"向 美国消费者销售药物，并视情况考虑从他国进口低价药品；打击全球搭便车现象，遏制他国压低药价、转嫁研发成本至美国的做法；如果药企不配合，将采 取立法、监管、进口等手段，全方位推动价格改革。 "最惠国价格"是指经合组织（OECD）国家内的最优惠价格。 陈东在美国制药行业工作超过20年，目前负责某中国创新药企在美业务，该药企有产品在美销售。他告诉经济观察报，美国的医保分为Medicare（联邦医疗 保险）、 Medicaid（医疗救助）和Commercial Insurance（商业保险）。Medicare为65岁以上的老年人、符合条件的残疾人提供保障，约占美国医疗支付的 30%；Medicaid占医疗支付的10%；Commercial Insurance占医疗支付比例超过40%。前述行政令只对Medicare和Medicaid产生直接影响。 陈东周围有不少同事、同行都在讨论"最惠国 ...

今日是关税会议后的首个交易日，A股三大指数涨跌不一，截至收盘，沪指涨0.17%，深成指跌0.13%，创业板指跌0.12%，北证50指数跌0.94%。 全市场成交额13260亿元，较上日缩量149亿元。 板块题材上，港口航运、光伏设备、银行、医疗服务、贵金属板块涨幅居前；军工、人形机器人、智能交通、铜缆高速连接概念股跌幅居前。 昨夜美股在中美关税会议后迎来大涨，标普500指数涨3.26%；道琼斯指数涨2.81%；纳斯达克指数涨4.35%。 值得一提的是，道指和标普的年内跌幅已分别收窄至0.32%和0.64%，纳指的累计跌幅为3.12%，但该指数较上月低位反弹超20%。 避险资产黄金周一暴跌近3%，主要原因在于美中宣布贸易战暂时"休兵"，今日早盘现货黄金延续跌势。 01 美对中关税 还余30% 昨日收盘后，中美日内瓦经贸会谈联合声明发布，从结果来看，无论是时间，速度还是降低关税的幅度都超出了市场预期，港股一度直线拉升涨超 6%。 5月13日，开盘后市场表现平淡。从大盘上来看，上证指数、恒生指数早已站上4月2日"对等关税"之前的位置，此次超预期利好也被市场解读为利 好出尽。 民生证券最新研报表示，美国对华关税，从 ...

Group 1 - The Hang Seng Medical Index ETF has shown significant liquidity with a turnover of 5.27% and a transaction volume of 13.6062 million yuan, with an average daily transaction volume of 28.9853 million yuan over the past month [2] - The ETF has experienced a notable increase in scale, growing by 1.7471 million yuan over the past week, ranking first among comparable funds, with the latest share count reaching 218 million, a new high for the past month [2] - The ETF has seen continuous net inflows over the past four days, with a maximum single-day net inflow of 6.1016 million yuan, totaling 13.3303 million yuan [2] Group 2 - The price-to-earnings ratio (PE-TTM) of the Hang Seng Medical Healthcare Index is currently at 23.35, which is in the 3.64% percentile for the past year, indicating that the valuation is lower than 96.36% of the time in the past year, suggesting a historical low [2] - The top ten weighted stocks in the Hang Seng Medical Healthcare Index include WuXi AppTec, Innovent Biologics, BeiGene, and others, collectively accounting for 56.03% of the index [2] Group 3 - The domestic medical device industry is still in a rapid development phase, with short-term impacts from medical insurance cost control potentially affecting the sector negatively, but there is optimism for innovation-driven import substitution and global development [3] - The industry is expected to see improved competitiveness among domestic companies due to policy support and technological advancements, accelerating import substitution [3] - Investors without stock accounts can consider the Hang Seng Medical Index ETF linked fund (018433) to gain exposure to investment opportunities in the Hong Kong medical sector [3]

Core Viewpoint - The recent policy announced by Trump to align U.S. drug prices with the lowest global prices could lead to a significant decrease in prescription drug prices in the U.S., potentially by 30% to 80%, raising concerns among pharmaceutical companies, especially those exporting to the U.S. [1][2] Group 1: Market Performance - As of May 13, 2025, the CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Composite Index (930965) rose by 2.42%, with notable increases in stocks such as BeiGene (06160) up 4.15% and Innovent Biologics (01801) up 3.14% [1] - The Hong Kong Pharmaceutical ETF (159718) opened high and increased by 2.04%, with a latest price of 0.70 yuan, and a one-month cumulative increase of 3.32% [1] - The CSI Pharmaceutical and Medical Device Innovation Index (931484) increased by 0.87%, with stocks like East China Pharmaceutical (000963) rising by 2.23% [4] Group 2: Trading Volume and Liquidity - The Hong Kong Pharmaceutical ETF had a turnover of 1.72% during the trading session, with a transaction volume of 4.0999 million yuan, and an average daily transaction volume of 95.7602 million yuan over the past month [1] - The latest scale of the Medical Innovation ETF (516820) reached 1.588 billion yuan [4] Group 3: Index Composition - The top ten weighted stocks in the CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Composite Index accounted for 60.54% of the index, including BeiGene (06160) and WuXi Biologics (02269) [5] - The top ten weighted stocks in the CSI Pharmaceutical and Medical Device Innovation Index represented 66.51% of the index, featuring companies like Hengrui Medicine (600276) and WuXi AppTec (603259) [8]